Conference Roundup

Half dose of teprotumumab shows potential in active moderate-to-severe TED

In a poster presented at AAO 2022, researchers highlighted the first reported successful treatment of active moderate-to-severe thyroid eye disease (TED with half a dose of teprotumumab. This case has led researchers to consider the potential benefit of reducing teprotumumab dosage to decrease the likelihood of teprotumumab-induced hearing loss. In...